Literature DB >> 33829465

Therapeutic potential of N-acetyl cysteine (NAC) in preventing cytokine storm in COVID-19: review of current evidence.

R R Mohanty1, B M Padhy, S Das, B R Meher.   

Abstract

Since November 2019, SARS Coronavirus 2 disease (COVID-19) pandemic has spread through more than 195 nations worldwide. Though the coronavirus infection affects all age and sex groups, the mortality is skewed towards the elderly population and the cause of death is mostly acute respiratory distress syndrome (ARDS). There are data suggesting the role of excessive immune activation and cytokine storm as the cause of lung injury in COVID-19. The excessive immune activation and cytokine storm usually occurs due to an imbalance in redox homeostasis of the individuals. Considering the antioxidant and free radical scavenging action of N acetyl cysteine (NAC), its use might be useful in COVID-19 patients by decreasing the cytokine storm consequently decreasing the disease severity. Therefore, we reviewed all the available resources pertaining to the role of reactive oxygen species (ROS) in cytokine storm and the mechanism of action of NAC in preventing ROS. We also reviewed the use of NAC in COVID-19.

Entities:  

Year:  2021        PMID: 33829465     DOI: 10.26355/eurrev_202103_25442

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  6 in total

Review 1.  Use of Thiols in the Treatment of COVID-19: Current Evidence.

Authors:  Mario Cazzola; Paola Rogliani; Sundeep Santosh Salvi; Josuel Ora; Maria Gabriella Matera
Journal:  Lung       Date:  2021-08-27       Impact factor: 2.584

Review 2.  Advances in the Regulation of Macrophage Polarization by Mesenchymal Stem Cells and Implications for ALI/ARDS Treatment.

Authors:  Chang Liu; Kun Xiao; Lixin Xie
Journal:  Front Immunol       Date:  2022-07-08       Impact factor: 8.786

Review 3.  N-Acetylcysteine and Other Sulfur-Donors as a Preventative and Adjunct Therapy for COVID-19.

Authors:  Heidi N du Preez; Colleen Aldous; Hendrik G Kruger; Lin Johnson
Journal:  Adv Pharmacol Pharm Sci       Date:  2022-08-10

Review 4.  The potential role of ischaemia-reperfusion injury in chronic, relapsing diseases such as rheumatoid arthritis, Long COVID, and ME/CFS: evidence, mechanisms, and therapeutic implications.

Authors:  Douglas B Kell; Etheresia Pretorius
Journal:  Biochem J       Date:  2022-08-31       Impact factor: 3.766

5.  A pilot study on intravenous N-Acetylcysteine treatment in patients with mild-to-moderate COVID19-associated acute respiratory distress syndrome.

Authors:  Abbas Taher; Marjan Lashgari; Ladan Sedighi; Farshid Rahimi-Bashar; Jalal Poorolajal; Maryam Mehrpooya
Journal:  Pharmacol Rep       Date:  2021-06-10       Impact factor: 3.024

6.  Repurposing the antioxidant and anti-inflammatory agent N-acetyl cysteine for treating COVID-19.

Authors:  Josef Finsterer; Fulvio A Scorza; Carla A Scorza; Ana C Fiorini
Journal:  World J Virol       Date:  2022-01-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.